
Shares of Abbott Laboratories ABT.N fall 2.85% to $126.19
A judge in the Whitfield infant formula case granted a retrial to the plaintiffs following the October 31, 2024 verdict that handed a unanimous win in favor of Abbott and Reckitt's RKT.L unit Mead Johnson
The ruling found the companies were not liable for failing to warn of the risks around necrotizing enterocolitis (NEC) in their infant formula products
Today's ruling marks a setback following what seemed like a step in the right direction - J.P.Morgan
ABT shares up ~8% in the last 12 months